Aptorum Group Extends DiamiR Merger Agreement to June 2026
Summary
Aptorum Group has extended the termination date for its merger agreement with DiamiR Biosciences Corp. to June 30, 2026, indicating continued efforts to finalize the strategic transaction.
Key Events
-
Merger Agreement Extended
The termination date for the Agreement and Plan of Merger with DiamiR Biosciences Corp. has been extended from December 31, 2025, to June 30, 2026.
-
Related Agreements Also Extended
Concurrently, the Management Services Agreement and Intellectual Property License Agreement, both related to the merger, have also been extended to June 30, 2026.
-
Ongoing Merger Process
This extension confirms that Aptorum Group and DiamiR Biosciences are continuing to work towards satisfying the closing conditions for the merger, which was initially announced on July 14, 2025.
Analysis
This amendment signals continued commitment to the previously announced merger with DiamiR Biosciences. For a micro-cap company like Aptorum Group, the successful completion of this merger is a significant strategic event. The extension of the termination date from December 31, 2025, to June 30, 2026, indicates that while the process has been delayed, both parties are still actively working towards satisfying the closing conditions, preventing the deal from expiring. Investors should monitor further updates regarding the merger's progress.
At the time of this filing, APM was trading at $1.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $0.65 to $4.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.